Cronos Group Inc vs MasTec Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 14.7× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and MasTec Inc for 23 Days on average.
| CRON | MTZ | |
|---|---|---|
Market Cap | $1.18B | $17.40B |
Volume | 968,037 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $3.55 | $437.51 |
52-Week Low | $2.30 | $190.08 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $387.62M | $20.32B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, amid a bearish technical signal. The stock shows mixed earnings history, with recent beats in Q1 and Q2 2026 but a miss in Q4 2025. Revenue growth is robust, increasing from $118M in 2024 to $147M in 2025, with a projected rise to $179M in 2026. However, profitability remains volatile, with a net loss of $9.45M in 2025 despite a strong gross margin of 45.86%. Recent news highlights the company's Investor Day focusing on global expansion and cash flow generation.
The outlook for CRON is cautiously optimistic, driven by international growth and a debt-free balance sheet with $827M in cash. Key risks include ongoing profitability challenges, competitive pressures, and regulatory uncertainties in the cannabis sector. Analyst sentiment is mixed, with 60% hold ratings, suggesting a wait-and-see approach. Investors should weigh strong revenue trends against execution risks and margin volatility.
MasTec (MTZ) trades at $216.66, down 3.0% on the day, amid bearish technical signals despite strong analyst support. The stock shows mixed earnings performance with recent Q2 2026 EPS missing expectations, but maintains robust revenue growth projections and a record $21.4B backlog. Current valuation metrics include a P/E of 34.5 and P/S of 1.06, while profitability metrics show a 3.07% net income margin and 15.39% ROE.
The investment outlook remains positive based on strong analyst consensus (88.9% buy ratings) and a $408.58 price target, representing significant upside potential. Key opportunities include infrastructure investment cycles and AI-driven data center demand, while risks include premium valuation, weak cash flow trends, and communications segment softness. The stock's current price near support levels offers potential entry points for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →